ReviewFrontiers in public health2020
Bee Venom-A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections.
Review in Frontiers in public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.Immunity, inflammation and disease · 2021Pooled it
- Antimicrobial Peptides Against Arboviruses: Mechanisms, Challenges, and Future Directions.Probiotics and antimicrobial proteins · 2025Review
- Unlocking the Potential of RNA Sequencing in COVID-19: Toward Accurate Diagnosis and Personalized Medicine.Diagnostics (Basel, Switzerland) · 2025Review
- Natural Sources of Therapeutic Agents Used in Skin Conditions.Life (Basel, Switzerland) · 2024Review
- The current landscape of the antimicrobial peptide melittin and its therapeutic potential.Frontiers in immunology · 2024Review
- Antiviral attributes of bee venom as a possible therapeutic approach against SARS-CoV-2 infection.Future virology · 2023Review
- Review
- Bee venom as an alternative for antibiotics against Staphylococcus aureus infections.Scientific reports · 2023Article
- Impact of COVID-19 Pandemic on Tourist Travel Risk Perception and Travel Behaviour: A Case Study of Poland.International journal of environmental research and public health · 2023Article
- The potential role of scavenger receptor B type I (SR-BI) in SARS-CoV-2 infection.Immunity, inflammation and disease · 2023Review
- Review
- Therapeutic Use of Bee Venom and Potential Applications in Veterinary Medicine.Veterinary sciences · 2023Review
- Pharmacological properties and therapeutic potential of honey bee venom.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Review
- Pharmacokinetic improvement provided by microneedle patch in delivering bee venom, a case study in combating scopolamine-induced neurodegeneration in mouse model.Drug delivery · 2022Article
- Natural toxins and One Health: a review.Science in One Health · 2022Review
- Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection.Scientific reports · 2022Article
- Review
- Article
- Melittin-Based Nano-Delivery Systems for Cancer Therapy.Biomolecules · 2022Review
- Pharmacological effects and mechanisms of bee venom and its main components: Recent progress and perspective.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by severe cytokine storm syndrome following inflammation. SARS-CoV-2 directly interacts with angiotensin-converting enzyme 2 (ACE-2) receptors in the human body. Complementary therapies that impact on expression of IgE and IgG antibodies, including administration of bee venom (BV), have efficacy in the management of arthritis, and Parkinson's disease. A recent epidemiological study in China showed that local beekeepers have a level of immunity against SARS-CoV-2 with and without previous exposure to virus. BV anti-inflammatory properties are associated with melittin and phospholipase A2 (PLA2), both of which show activity against enveloped and non-enveloped viruses, including H1N1 and HIV, with activity mediated through antagonist activity against interleukin-6 (IL-6), IL-8, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α). Melittin is associated with the underexpression of proinflammatory cytokines, including nuclear factor-kappa B (NF-κB), extracellular signal-regulated kinases (ERK1/2), and protein kinase Akt. BV therapy also involves group III secretory phospholipase A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.